13th Jan 2016 09:38
LONDON (Alliance News) - Specialty pharmaceuticals company Allergy Therapeutics PLC on Wednesday said its revenue grew in the first half, with good organic sales growth.
The company said its revenue for the half to the end of December is set to be around GBP31.5 million, up from GBP28.2 million, with constant currency revenue growth at 12%.
Allergy, which its developing allergy vaccines, said the organic, constant currency growth was driven by a good trading performance for the group, with its market share increasing in all its European markets, boosted by the acquisition of Alerpharma in June.
The group expects its revenue for the year to meet market expectations, despite a drag from the weak euro.
Allergy shares were untraded on Wednesday morning, having last traded at 29.00 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Allergy Thera.